Frequency Therapeutics

David Lucchino, Co-Founder, President and CEO
Woburn, MA
(Private)

Frequency Therapeutics is a clinical-stage company harnessing the body’s innate regenerative biology with its Progenitor Cell Activation (PCA) regenerative platform. Frequency has successfully completed a first-in-human study of FX-322, the company’s lead PCA candidate for hearing restoration. The Phase I study provided crucial data on safety and pharmacokinetics associated with intratympanic delivery of FX-322 as the company moves forward toward additional clinical trials in the US to monitor clinical response. Frequency expects to initiate Phase II clinical work for its hearing regeneration program in 2H 2018. Frequency announced a three-way partnership with the US Army and the Harvard Stem Cell Institute to investigate small molecule regeneration for several disease indications involving muscle. The company also announced a Juvenile Diabetes Research Foundation award for the development of small molecule approach to create insulin and GLP-1 secreting cells. The company has secured $45M in financing. www.frequencytx.com